Pacira BioSciences Inc (PCRX)
26.33
+0.83
(+3.25%)
USD |
NASDAQ |
Apr 26, 16:00
26.35
+0.02
(+0.08%)
After-Hours: 20:00
Pacira BioSciences Net Income (Quarterly): 24.87M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 24.87M |
| September 30, 2023 | 10.86M |
| June 30, 2023 | 25.76M |
| March 31, 2023 | -19.54M |
| December 31, 2022 | -10.10M |
| September 30, 2022 | -0.693M |
| June 30, 2022 | 19.88M |
| March 31, 2022 | 6.828M |
| December 31, 2021 | -5.13M |
| September 30, 2021 | 17.66M |
| June 30, 2021 | 19.08M |
| March 31, 2021 | 10.37M |
| December 31, 2020 | 14.52M |
| September 30, 2020 | 130.12M |
| June 30, 2020 | -7.269M |
| March 31, 2020 | 8.159M |
| December 31, 2019 | -4.888M |
| September 30, 2019 | -6.087M |
| June 30, 2019 | 2.73M |
| March 31, 2019 | -2.771M |
| December 31, 2018 | 8.285M |
| September 30, 2018 | -0.64M |
| June 30, 2018 | 2.564M |
| March 31, 2018 | -10.68M |
| December 31, 2017 | 4.595M |
| Date | Value |
|---|---|
| September 30, 2017 | -7.597M |
| June 30, 2017 | -19.74M |
| March 31, 2017 | -19.87M |
| December 31, 2016 | -3.972M |
| September 30, 2016 | -22.16M |
| June 30, 2016 | -7.958M |
| March 31, 2016 | -3.854M |
| December 31, 2015 | -2.498M |
| September 30, 2015 | 3.086M |
| June 30, 2015 | 0.008M |
| March 31, 2015 | 1.26M |
| December 31, 2014 | 5.802M |
| September 30, 2014 | -3.004M |
| June 30, 2014 | -5.037M |
| March 31, 2014 | -11.48M |
| December 31, 2013 | -11.96M |
| September 30, 2013 | -14.78M |
| June 30, 2013 | -14.03M |
| March 31, 2013 | -23.14M |
| December 31, 2012 | -16.35M |
| September 30, 2012 | -15.74M |
| June 30, 2012 | -8.296M |
| March 31, 2012 | -11.89M |
| December 31, 2011 | -15.28M |
| September 30, 2011 | -9.508M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-19.54M
Minimum
Mar 2023
130.12M
Maximum
Sep 2020
12.48M
Average
8.159M
Median
Mar 2020
Net Income (Quarterly) Benchmarks
| Dynavax Technologies Corp | 0.219M |
| Arbutus Biopharma Corp | -19.31M |
| Chimerix Inc | -18.16M |
| Karyopharm Therapeutics Inc | -41.84M |
| FibroGen Inc | -56.23M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 181.24M |
| Total Expenses (Quarterly) | 147.28M |
| EPS Diluted (Quarterly) | 0.52 |
| Enterprise Value | 1.430B |
| Gross Profit Margin (Quarterly) | 73.69% |
| Profit Margin (Quarterly) | 13.72% |
| Earnings Yield | 3.15% |
| Operating Earnings Yield | 6.05% |
| Normalized Earnings Yield | 4.292 |